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Signal transduction across the plasma membrane is a critical
factor in the regulation of eukaryotic cells. A wealth of published studies have documented the role of exogenous hormones or neurotransmitters in the activation of such signaling
pathways. By contrast, the importance of autocrine/paracrine
signaling pathways in the regulation of cell function is often
under appreciated because of the more dramatic effects of
hormones and neuronal mediators. However, many cell types
produce and/or release chemical mediators that can dramatically alter function of the same or nearby cells (1). Such local
signaling events have the potential to sensitize or desensitize
cells via cross-talk between signaling cascades or to propagate
signals between cells based on release of mediators or direct
cell to cell communication. Prostaglandins, derived from the
conversion of arachidonic acid (AA)1 by cyclooxygenase, are an
example of such an autocrine/paracrine mechanism and are
recognized to arise from physical perturbation of cell surfaces.
Prostaglandins activate a diverse class of G protein-coupled
receptors that increase cytoplasmic Ca2⫹ and regulate adenylyl
cyclase activity (2).
Cells also can release nucleotides, such as ATP and UTP, in
response to mechanical stress or biological activation (3–9).
However, the role of released nucleotides (in contrast to exogenously added agents) in modulation of cell signaling pathways
has not been defined. Specific targets for nucleotides include
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P2Y (G protein-coupled) and P2X (ion channel) receptors (10,
11). Although P2X and P2Y receptors have been identified in
many cell types, their contribution to basal levels of ion conductance or activation of G protein-coupled effectors is not
known. Release of ATP and activation of P2Y receptors has
been implicated as a gap junction-independent mechanism for
transducing waves of intracellular Ca2⫹ signals in various cell
types (12, 13).
In the present studies, we have examined ATP release, P2Y
receptors, and signal transduction pathways in Madin-Darby
canine kidney (MDCK-D1) cells, a well differentiated and
widely utilized model system derived from distal tubule/collecting duct epithelium. P2Y1 and P2Y2 receptor subtypes are
expressed in MDCK-D1 cells and couple to phospholipase C,
presumably via activation of Gq/11 family G proteins (14). P2Y11
receptors are also expressed in these cells and have been suggested to couple to Gq as well as Gs in other cells (15). In
MDCK-D1 cells P2Y receptor agonists decrease membrane resistance, increase intracellular calcium, regulate ion transport,
activate protein kinase C, and couple to the activation of cytosolic phospholipase A2 (cPLA2) via both mitogen-activated protein kinase-dependent and -independent pathways (13, 16 –19).
cPLA2-mediated release of AA provides substrate for cyclooxygenase conversion into eicosanoids, in particular PGE2, which
then activates adenylyl cyclase activity through Gs-coupled
prostanoid receptors (20). In the present experiments we tested
whether nucleotides might be released by MDCK cells and
thereby alter levels of second messengers via activation of P2Y
receptors. We find that MDCK-D1 cells release ATP in response
to mild mechanical manipulation, thereby resulting in substantial basal release of arachidonic acid as well as an increase in
the cellular levels of cAMP. We further find that HEK-293 and
COS-7 cells also release ATP. Therefore, release of ATP by
physical or chemical means contributes to the set-point of the
cellular signaling pathways regulated by P2Y receptors. The
results have important implications for released ATP as a
modulator of signal transduction pathways in epithelial and
other cell systems.
EXPERIMENTAL PROCEDURES

Materials—Cell culture reagents were obtained from Fisher. Radiolabeled chemicals were obtained from NEN Life Science Products. Forskolin was obtained from Calbiochem. ATP bioluminescence assay kit
HS II was obtained from Roche Molecular Biochemicals. All other drugs
and reagents were obtained from Sigma.
Cell Culture—MDCK-D1 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 2.5% fetal bovine serum
and 7.5% horse serum. Cells were passaged every 3– 4 days by
trypsinization using trypsin/EDTA. Cells were used for experiments in
24-well plates (Costar) grown to approximately 60 –70% confluence. In
some experiments, cells were washed and cultured in serum-free
DMEM for 24 – 48 h before assay.
Assay of cAMP—Cells were labeled with 1 Ci/well [3H]adenine in
growth medium for 90 min to allow incorporation of radiolabel into
intracellular ATP pools. Growth medium was removed, and cells were
washed extensively and equilibrated for 30 min at 37 °C in serum-free
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The determinants of “basal” activity of signaling pathways regulating cellular responses are poorly defined.
One possibility is that cells release factors to establish
the set-point of such pathways. Here we show that treatment of Madin-Darby canine kidney cells with the nucleotidase apyrase decreases basal arachidonic acid release and cAMP production 30 – 40% and that inhibitors
of P2Y receptor action also affect basal and forskolinstimulated cAMP accumulation. Changing medium
prominently increases extracellular levels of ATP in Madin-Darby canine kidney, COS-7, and HEK-293 cells. Mechanical stimulation of ATP release likely occurs in virtually every experimental protocol with cultured cells,
implicating such release and P2Y receptor activation as
critical in establishing the set-point for signal transduction pathways.
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RESULTS

Cyclic AMP Accumulation in MDCK-D1 Cells
Effect of Cyclooxygenase Inhibition—We measured cAMP accumulation under basal and forskolin-stimulated conditions in
MDCK-D1 cells pretreated for 20 min in the absence or presence of indomethacin (1 M). As shown in Fig. 1A, we found that
basal levels of cAMP production were reduced 40% by incubation of the cells with indomethacin, whereas this treatment
inhibited forskolin-stimulated (10 M) response by almost 60%.
A different cyclooxygenase inhibitor, aspirin (100 M), inhibited basal and forskolin-stimulated cAMP accumulation in a
similar fashion (data not shown). We analyzed cAMP production under unstimulated and forskolin-stimulated conditions
as a measure of the basal activity state of adenylyl cyclase,
taking advantage of the ability of forskolin to potentiate Gs
activation of this enzyme by enhancing the coupling of Gs to
adenylyl cyclase (23, 24). These results indicate that appreciable AA metabolites are generated by MDCK-D1 cells in the
basal state and that these metabolites substantially contribute
to both basal and forskolin-stimulated cAMP generation. The
latter finding implies that cellular response to forskolin, commonly assumed to measure catalytic activity of adenylyl cyclase (25), can include a substantial contribution of G proteincoupled receptor, in particular prostaglandin receptor,
activation.
We examined whether cyclooxygenase-derived AA metabo-

FIG. 1. Sensitivity of cAMP formation to cyclooxygenase inhibition. A, cAMP accumulation was measured in either control (solid
bars) and indomethacin-treated (1 M, hatched bars) MDCK-D1 cells.
Inset, cAMP responses were measured in the presence of a low, sensitizing concentration of forskolin (0.1 M). B, cAMP accumulation concentration response curves to phenylephrine (circles) and bradykinin
(squares) in control (closed symbols) or indomethacin-treated (open symbols) MDCK-D1 cells. The lines represent fit of the data using nonlinear
regression analysis. Each point is mean ⫾ S.E. of 3–5 experiments.

lites play a role in response to agonists that activate cPLA2 in
MDCK cells (19, 26, 27). ATP (100 M), UTP (100 M), phenylephrine (1 M), and bradykinin (1 M) each stimulated cAMP
production, and these responses were substantially inhibited
by indomethacin (Fig. 1A). When these agonists were combined
with a low concentration of forskolin (0.1 M), indomethacin
eliminated responses to UTP, phenylephrine, and bradykinin
(Fig. 1A, inset). The remaining levels of cAMP are the small
amounts stimulated by forskolin in the absence of synergy from
activated Gs (i.e. forskolin in the presence of indomethacin).
The exception is the response to ATP, which activates a sizable
indomethacin insensitive-cAMP response (20). Varying concentrations of phenylephrine and bradykinin were tested for their
ability to stimulate cAMP production in either control cells or
cells preincubated with indomethacin (1 M). To control for the
possibility that phenylephrine may activate ␤-adrenergic receptors, the ␤-blocker propranolol (1 M) was included in these
drug conditions. Phenylephrine stimulated cAMP accumulation with an EC50 of 23 nM and a maximal response about 50%
over basal levels (Fig. 1B). Bradykinin activated cAMP production with similar potency (EC50 ⫽ 22 nM) but was more efficacious, stimulating almost 3-fold increases in cAMP levels. Indomethacin completely eliminated cAMP responses to both of
these agonists, indicating that these effects are attributable to
cyclooxygenase-derived AA metabolites. Thus, bradykinin and
␣1-adrenergic receptors, as well as P2Y2 receptors, increase
cAMP formation in MDCK-D1 cells in a cyclooxygenase-de-
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DMEM containing 20 mM HEPES buffer (DMEH). Cells were then
incubated for 5 min in fresh DMEH with either 200 M isobutylmethylxanthine or 100 M Ro 20-1724 (to inhibit phosphodiesterases) along
with various drugs of interest. Reactions were terminated by aspiration
of medium and addition of 7.5% trichloroacetic acid. Approximately
1000 cpm of [32P]cAMP internal standard was added to each sample,
and the volume was brought to 1 ml with water. [3H]cAMP and [3H]ATP
were separated from the supernatant fraction using a chromatography
method modified from Salomon et al. (21) and as described previously
(22).
Luciferin/Luciferase Detection of ATP—For luciferin/luciferase detection of ATP, cells were preincubated for 30 min in 0.5 ml of DMEH
at 37 °C. Media were then gently aspirated without tilting the plate,
and fresh media containing the indicated drugs were gently added to
the side of the well. In time course experiments, 100 l of medium was
collected from the top of each well at the indicated time, making sure to
avoid contact of the pipette tip with the cells. When drug effects were
measured, cells were equilibrated for 60 min in media, a small volume
of drug was gently applied, and then 100 l of medium was collected 5
min later. All samples were centrifuged to eliminate possible cell contaminants. An ATP bioluminescence kit containing luciferin/luciferase
reagent was used to detect ATP (ATP bioluminescence assay kit HS II,
Roche Molecular Biochemicals), and luminescence was measured in a
Monolight 2010 luminometer. Bioluminescence controls were performed with each drug solution to eliminate drug effect on luciferase
activity as well as to control for ATP contamination.
[3H]AA Release in Intact Cells—Cells were labeled with [3H]AA by
incubation with 0.5 Ci of [3H]AA (specific activity 100 Ci/mmol) per ml
for approximately 20 h in 24-well plates. Cells were washed three times
with DMEH, pH 7.4, supplemented with 5 mg/ml bovine serum albumin
and allowed to equilibrate at 37 °C for 15 min. This equilibration
medium was aspirated, and drugs of interest were added to the wells
and incubated with cells for 20 min. Assays were terminated by removal
of medium and transferring this medium into tubes containing 50 l of
55 mM EDTA, 55 mM EGTA. 250 l of 0.5% Triton X-100 was added to
each well to solubilize cellular membranes. Liquid scintillation counting was performed to quantitate released [3H]AA in media. The results
were normalized as a percentage of incorporated radioactivity measured from detergent-solubilized cells.
Data Presentation and Analysis—Data were obtained in triplicate,
averaged for each condition in an experiment, and are presented as the
mean ⫾ S.E. of at least three experiments. Paired t test was used to
determine statistical significance. For concentration-response relationships, the data were fit by nonlinear regression analysis (with variable
slope) using Prism by GraphPad (San Diego, CA). EC50 and maximal
response are reported as the mean ⫾ S.E. of individual experiments.
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pendent manner. Such results define a mechanism, other than
activation of particular adenylyl cyclase isoforms directly via
G␤␥ subunits, Ca2⫹, or protein kinase C, whereby agonists that
couple to Gq can increase cAMP levels.
Effect of Apyrase—We investigated whether extracellular
nucleotides contribute to the indomethacin sensitivity of basal,
forskolin, and hormonal agonist-stimulated cAMP by assessing
cAMP accumulation in cells incubated with apyrase, a nucleotidase that can act extracellularly to dephosphorylate ATP and
ADP. Both basal and forskolin-stimulated cAMP accumulation
were substantially (38 and 29%, respectively) inhibited by incubation of cells with apyrase (2 units/ml) while, as expected,
ATP- and UTP-mediated responses were abolished (Fig. 2A).
Apyrase did not significantly inhibit cAMP generated in response to phenylephrine or bradykinin, indicating that extracellular nucleotides do not mediate the increases in cAMP
levels induced by these cPLA2-activating agonists. Combined
treatment with indomethacin and apyrase had no further effect
compared with indomethacin alone on basal or forskolin-mediated cAMP accumulation, while completely abolishing cAMP
generated by exogenous ATP and having no effect on that
stimulated by PGE2 (Fig. 2B). The nonadditivity of inhibition
by apyrase and indomethacin indicates that extracellular nucleotides act proximal to cyclooxygenase to increase basal and
forskolin-stimulated cAMP accumulation. We also tested
whether inhibition of other molecules involved in P2Y receptor
signal transduction would reduce basal and forskolin-stimulated cAMP accumulation. The P2Y receptor antagonist suramin (100 M) and protein kinase C inhibitor calphostin C (0.1
M) each reduced basal cAMP levels as did indomethacin (data
not shown).

FIG. 3. ATP release by various cell types in response to mechanical or biochemical perturbation. A and B, concentration of
ATP in the extracellular medium assayed at various times following a
medium change in MDCK-D1 (A) and HEK-293 or COS-7 cells (B,
HEK-293 (squares), COS-7 (circles)). C, ATP release stimulated by UTP,
phenylephrine, and bradykinin expressed as fold over basal in
MDCK-D1 (solid bars), HEK-293 (hatched bars), and COS-7 cells (open
bars). D, concentration of ATP in the extracellular medium following
addition of various concentrations of UTP in MDCK-D1 cells. Line
represents fit of the data using nonlinear regression analysis with a
fixed Bmax. Each point or bar represents the mean ⫾ S.E. of 3– 6
experiments. *, p ⬍ 0.05; **, p ⬍ 0.01 by paired t test as compared with
control condition.

ATP Release from MDCK-D1, COS-7, and HEK-293 Cells
To assess directly whether ATP was released from cells under basal conditions, we measured ATP release into the extracellular medium by using a sensitive luciferin/luciferase assay.
A gentle medium change released sizable quantities of ATP
from MDCK-D1 cells, reaching a concentration of 45 ⫾ 12 nM
within 2 min. The concentration of extracellular ATP decreased
to 2.3 ⫾ 0.5 nM in medium from cells incubated at 37 °C undisturbed for 60 min following medium change, presumably due to
ecto-ATPase/nucleotidase activity (Fig. 3A). Our assays for
cAMP accumulation were determined approximately 5 min
following a medium change, a time at which extracellular ATP
concentrations were at a peak. Thus, release of ATP in response to a change of media likely accounts for the sensitivity
to indomethacin and apyrase of both basal and forskolin-stimulated cAMP accumulation (Figs. 1A and 2A). In cells incubated undisturbed for 60 min, ATP release increased 3.3 ⫾
0.5-fold (to 8.6 nM) when the plate was tilted to sample extracellular medium. COS-7 and HEK-293 cells also released large
amounts of ATP following a gentle media change, with ATP
concentrations remaining as high as 66 nM after 60 min (Fig.
3B). These and other data (9, 28) indicate that ATP release
occurs in many cells types. We hypothesize that signal transduction in these widely utilized cell models is effected by mechanical stimulation and release of nucleotides.
Release of ATP in MDCK cells was stimulated 30 ⫾ 3-fold
over basal by the addition of UTP (100 M) and 6.8 ⫾ 0.8- and
2.4 ⫾ 0.5-fold by the addition of phenylephrine (1 M) and
bradykinin (1 M), respectively (Fig. 3C). Addition of forskolin
(10 M) inhibited ATP release slightly (26 ⫾ 19%, p ⫽ 0.18)
while PGE2 (1 M) had no effect (data not shown). UTP and
bradykinin also increased extracellular levels of ATP in COS-7
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FIG. 2. Sensitivity of cAMP formation to the hydrolysis of extracellular nucleotides. A, cAMP accumulation was measured in
either the absence (solid bars) or the presence (hatched bars) of 2
units/ml apyrase. B, cAMP accumulation was measured in control (open
bars), indomethacin-treated (1 M, shaded bars), apyrase-treated (2
units/ml, solid bars), or both indomethacin- and apyrase-treated
(hatched bars) MDCK-D1 cells. Each bar represents the mean ⫾ S.E. of
3– 6 experiments. *, p ⬍ 0.05; **, p ⬍ 0.01 by paired t test as compared
with control condition.
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and HEK-293 cells (Fig. 3C), albeit to a lesser extent than in
MDCK cells. Extracellular ATP concentrations were stimulated by UTP in a concentration-dependent manner (Fig. 3D)
and with a potency similar to the activation of PGE2 production
in MDCK cells (20). The effect of UTP in increasing ATP release in these experiments may also represent an ability of
UTP to convert ADP to ATP via nucleoside diphosphokinases
or to act as a competitive inhibitor for the catalysis of ATP,
thereby increasing the amount of ATP detected. Irrespective of
the mechanism for the effect of UTP, the increase in ATP levels
adds an important complexity to interpretation of studies that
assess effects of UTP on signal transduction and cellular responses (10, 29). As UTP-promoted ATP transport has recently
been reported (30), we speculate that aspects of cellular responses previously attributed to UTP may be, in part, secondary to increases in extracellular ATP.

Arachidonic Acid Release from MDCK-D1 Cells: Effect of
Apyrase

DISCUSSION

The present studies were designed to test the hypothesis that
nucleotide release and, in turn, activation of P2 receptors are
important for the autocrine/paracrine regulation of signal
transduction mechanisms in native cells. The results document
that such release plays a major role in determining basal cAMP
levels and that release can be promoted by both physical and
chemical means, the latter findings consistent with other data
(as recently reviewed in Ref. 31). In the case of epithelial cells,
such as MDCK cells, release of ATP may be of particular
importance both physiologically and pathophysiologically because P2Y receptors can influence ion conductance and volume
regulation and may contribute to chloride conductance in cells
with mutations of the cystic fibrosis transmembrane conductance regulator (31–33). In addition, extracellular ATP may
augment cyst enlargement in autosomal dominant polycystic
kidney disease through stimulation of epithelia that line the
cyst lumen (34). Despite the potentially key importance of
ATP/nucleotide release with respect to cell signaling and function, the precise mechanism for such release, other than by
exocytosis at synapses and blood platelets or by cell injury,
remains poorly defined (31).
The effects of extracellular ATP, as well as nucleotides such
as UTP, are dependent upon several factors. The type of P2
receptors expressed on a cell will determine the nature of the
resulting signal. Thus far, six G protein-coupled P2Y receptors
(coupled predominantly to the Gq family of heterotrimeric G
proteins but also to Gi/o and possibly Gs) and seven P2X receptors (ATP-gated ion channels permeable to Ca2⫹) have been
identified (35, 36). Also important is the expression of ecto-

ATPases and other ecto-nucleotidases. Two ecto-ATPase forms
have been defined biochemically, one that hydrolyzes ATP to
ADP and another that breaks down both triphosphate and
diphosphate nucleotides (37, 38). Given that different isoforms
of the P2Y receptor display different affinities for ADP and
ATP and their analogs, the form of ecto-ATPase/nucleotidase
expressed by a given cell likely confers different response profiles. In addition, released ATP can be hydrolyzed to adenosine,
which can activate P1 receptors (39).
The concentrations of released ATP that we measured may
be underestimated. Recent studies using a membrane-anchored method to detect ATP release in platelets (luciferase
was tethered to an ATP-binding cassette protein using an antibody) indicate that ATP concentrations near the cell surface
are many times higher than that detected in the bulk phase
(40). The rapid action of ecto-nucleotidases on the cell surface,
as well as membrane trapping and unstirred layer effects,
likely account for differences between assays of ATP in bulk
medium and those determined in the local environment of the
cell membrane. Our measurements would not detect this local
membrane concentration of ATP, as we sampled a small portion of the cell medium for the luciferase assay. Furthermore,
membrane trapping and unstirred layer effects might also explain the lower efficacy of apyrase in inhibiting basal and
forskolin-stimulated cAMP levels as compared with indomethacin, because apyrase in the bulk phase may not degrade
all cellularly released ATP prior to its activation of P2
receptors.
We demonstrate that both mechanical and chemical perturbations can alter the release of ATP, initiate P2Y receptor
signaling, and contribute to “basal” levels of second messengers
(Fig. 4). Because P2 receptors are widely expressed and ATP
release occurs in many cell types (3, 5–9, 28), our results imply
that such release is important in establishing the basal state of
cell signaling, in particular related to increases in calcium and
activation of calcium- and protein kinase C-mediated events
and, at least in certain cells as shown here, arachidonic acid
release and cAMP formation. Our findings extend to native
cells previous results that demonstrate mechanical stimulation
can increase phosphoinositide hydrolysis and calcium mobilization in cells that overexpress P2Y receptors (4). Moreover,
the ability of indomethacin or apyrase to substantially blunt
cAMP generation in response to forskolin is akin to the observed decrease in broken cell adenylyl cyclase activity assays
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Because both phenylephrine and bradykinin elicited ATP
release, we sought to determine whether ATP (or other nucleotide) release might contribute to basal release of AA or the
ability of those agents to enhance AA release (26, 27). Varying
concentrations of phenylephrine and bradykinin elicited release of AA and its metabolites in control conditions with EC50
values of 0.2 M and 9.9 nM, respectively, and with maximal
responses of 101 and 204% over basal, respectively (values
comparable with those observed for each agonist in mediating
cAMP responses shown in Fig. 1B). Addition of apyrase (2
units/ml) did not significantly alter phenylephrine- or bradykinin-stimulated AA release, indicating that release of extracellular nucleotides does not mediate AA release promoted by
␣1-adrenergic or bradykinin receptors (data not shown). By
contrast, basal AA release was inhibited 32% by incubation of
cells with apyrase, implicating nucleotide release as a critical
determinant of basal AA production.

FIG. 4. Schematic diagram of ATP release and action in
MDCK-D1 cells. Released ATP can promote cAMP production via P2Y
receptors through both calcium- and mitogen-activated protein (MAP)
kinase-dependent activation of cPLA2, leading to the generation of
prostaglandins that activate receptors coupled to the stimulation of
adenylyl cyclase (19, 20, 26, 27). These pathways are activated by
release of endogenous nucleotides in response to mechanical stimulation. PKC, protein kinase C; PLC, phospholipase C; DAG, diacylglycerol; PIP2, inositol 1,4,5-bisphosphate.

ATP Release Determines Basal Signal Transduction
as compared with cAMP generated in intact cell assays (25).
ATP release by intact cells may contribute to such differences
in forskolin response.
Considering that mild mechanical stimulation occurs during
virtually every experimental protocol with cultured cells as
well as in vivo, evidence that such stimulation can release ATP
and alter second messenger systems implies that release of
nucleotides is a critical factor in such systems and events they
regulate. These findings have even more profound implications
when one considers that released nucleotides may sensitize or
desensitize signaling pathways (29). Thus, release of ATP (or
other nucleotides (9)) likely provides an important means by
which cells regulate responsivity not only to nucleotides themselves but also to agonists that act via other hormone and
neurotransmitter receptors.
Acknowledgment—We thank Dr. Robert Tukey for use of the
luminometer.
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